- 02:32 PM PM talks growth, reforms; outlines stimulus exit p...
- 10:28 AM Financial stability, climate change top on EU Prez...
- 10:27 AM UK joins G20 push for world levy on banks
- 10:27 AM Britain urges divided G20 to reach climate finance...
- 10:27 AM G20 leaders meet, talk about climate change, world...
- 06:47 PM 'The Sensex will test 14500 at some point…'
- 04:16 PM See scope for more int'l listings of Indian cos: N...
- 04:12 PM Dollar weakness will boost EMs, commodities ahead:...
- 04:07 PM 'India would've grown at 7% had monsoon not played...
- 03:04 PM Bye-bye Circular 23!
Lupin Limited, announced today that its subsidiary in the US, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for the Company’s Abbreviated New Drug Application (ANDA) for Divalproex Sodium Delayed-Release Tablets, 125 mg, 250 mg and 500 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced.
Lupin’s Divalproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories’ Depakote® tablets. Depakote had annual sales of approximately $803 million for the twelve months ended March 2008, based on IMS Health sales data.
With the approval of Divalproex Sodium Delayed-Release Tablets, the cumulative ANDA approvals of the Company stand at 31 (including 3 tentative approvals) with 34 pending approvals from the USFDA.
Sourced From: The Source
|
|
Today's Special Column
with Kishore Biyani
Future Group and the MD of Pantaloon Retail (India) Limited , Group CEO
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 'The Sensex will test 14500 at some point…'
- Exit Suzlon Energy at Rs 83: Joshi
- Mahindra Satyam restarts hirings, recalls bench
- 'Bullish' Mark Mobius unfazed by recent market correction
- Sensex ends week 262 pts up, sectors to look at ahead
- SBI cuts deposit rates on slow credit, liquidity glut
- PM talks growth, reforms; outlines stimulus exit plan
Source: Moneycontrol.com
- 'The Sensex will test 14500 at some point…'
Source: CNBC-TV18
- See scope for more int'l listings of Indian cos: NYSE
Source: CNBC-TV18
- Dollar weakness will boost EMs, commodities ahead: HSBC
Source: CNBC-TV18
- SBI cuts deposit rates on slow credit, liquidity glut
Source: Business Line
- Aurobindo drug gets US nod
Source: Business Line
- BEML bags Rs 185 cr NCL order
Source: Business Line
- Tatas going global with low-cost housing
Source: Business Line
